QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s European Society for Medical Oncology (ESMO) congress in Copenhagen.
The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology.
BMS’s Opdivo and Merck’s Keytruda have been the sole PD-1 immunotherapies for the last two years, but Roche’s Tecentriq gained approval in May this year in urothelial carcinoma, a cancer of
Day three at the European Society for Medical Oncology 2016 congress belonged to Merck & Co., and may well be seen as a hugely significant day in the future of lung cancer treatment.
While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change